TAAR1 and cancer: The first phase I clinical trial with Tα1 was performed at the National Cancer Institute (11) while subsequent clinical trials were endorsed by the Biological Response Modifier Program (BRMP), within the Division of Cancer Treatment, with the responsibility to foster the development of biologicals, including thymosin fraction V and Tα1, that have therapeutic efficacy in cancer (12).